Skip to main content
Lisa Carey, MD, FASCO

Lisa A. Carey, MD, FASCO, the L. Richardson and Marilyn Jacobs Preyer Distinguished Professor for Breast Cancer Research, Division of Oncology and Deputy Director of Clinical Sciences for the Lineberger Comprehensive Cancer Center, discusses findings from a pooled analysis of the MONALEESA-2, -3, and -7 trials. Among the findings was a consistent overall survival benefit with ribociclib plus endocrine therapy for patients with luminal A, luminal B, and HER2E breast cancer subtypes. Patients with the basal-like subtype did not derive a benefit from ribociclib, but the sample size was small (Abstract GS1-04).

Watch her ASCO recorded discussion.